TRINETRA › Sectors › Healthcare
Bliss GVS Pharma Limited (BLISSGVS) — share price, P/E and fundamentals
Bliss GVS Pharma Limited (NSE: BLISSGVS) closed at ₹651.65 on 30 Oct 2026, +328.5% over one year, against a 52-week range of ₹118.00 – ₹739.90.
In the quarter ended 30 Sept 2026 (consolidated, filed 29 Oct 2026) it reported revenue of ₹313 cr and net profit of ₹52 cr, a 16.7% net margin; revenue grew 28.2% and profit grew 84.8% year on year.
On four consecutive filed quarters its trailing P/E is 43.0; since 13 May 2025 its own P/E has ranged from 14.8 to 57.3 (median 21.4), and today's reading is higher than 85% of those 363 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 16.2%, ROCE 23.2%, debt-to-equity 0.00, Piotroski F-score 7 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 62% of 64 sector peers; PBT margin higher than 67% of 64 sector peers; ROE higher than 66% of 64 sector peers.
Key figures
| Last close | ₹651.65 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -5.2% / +148.1% / +328.5% |
| 52-week low – high | ₹118.00 – ₹739.90 |
| Market capitalisation | ₹6,929 cr |
| Trailing P/E | 43.0 |
| Price / book | 5.37 |
| EV / EBITDA | 24.5 |
| Earnings yield | 2.3% |
| TTM EPS | ₹15.16 |
| TTM net profit | ₹161 cr |
| Quarter revenue | ₹313 cr |
| Quarter net profit | ₹52 cr |
| Net margin | 16.7% |
| Revenue growth (YoY) | +28.2% |
| Profit growth (YoY) | +84.8% |
| Return on equity | 16.2% |
| ROCE | 23.2% |
| Debt / equity | 0.00 |
| Current ratio | 4.35 |
| Free cash flow | ₹4 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹14.9 cr |
Against Healthcare peers
| Metric | BLISSGVS | Peer median | Percentile |
|---|---|---|---|
| Net margin | 16.67 | 12.89 | 63 |
| PBT margin | 23.96 | 17.68 | 67 |
| ROE | 16.20 | 13.87 | 66 |
| ROCE | 23.19 | 17.26 | 73 |
| Debt / equity | 0.00 | 0.11 | 12 |
| FCF margin | 0.67 | -0.87 | 53 |
| Cash conversion | 0.34 | 1.25 | 8 |
| Trailing P/E | 42.99 | 43.26 | 48 |
Questions
What is the P/E ratio of Bliss GVS Pharma Limited?
Bliss GVS Pharma Limited's trailing P/E is 43.0, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 13 May 2025 its P/E has ranged 14.8–57.3.
What were Bliss GVS Pharma Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Bliss GVS Pharma Limited reported revenue of ₹313 cr and net profit of ₹52 cr (consolidated), filed with the exchange on 29 Oct 2026.
What is Bliss GVS Pharma Limited's ROE?
Return on equity is 16.2% based on the balance sheet dated 30 Sept 2026.
Does Bliss GVS Pharma Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 30 Sept 2026.
What is BLISSGVS's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, BLISSGVS traded between ₹118.00 and ₹739.90.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.